{"id":"optalgin-voltaren-morphine","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Respiratory depression"}]},"_chembl":{"chemblId":"CHEMBL5665374","moleculeType":null,"molecularWeight":"285.34"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metamizole and diclofenac work through inhibition of cyclooxygenase enzymes to reduce prostaglandin production, thereby decreasing inflammation and pain signaling. Morphine acts as a mu-opioid receptor agonist in the central nervous system to modulate pain perception at multiple levels. Together, these agents provide multimodal analgesia for moderate to severe pain management.","oneSentence":"This is a combination of three distinct analgesic and anti-inflammatory agents: Optalgin (metamizole) inhibits prostaglandin synthesis, Voltaren (diclofenac) is an NSAID that blocks COX enzymes, and Morphine is an opioid mu-receptor agonist.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:58:28.012Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe acute pain"},{"name":"Post-operative pain management"}]},"trialDetails":[{"nctId":"NCT02689024","phase":"PHASE4","title":"Delirium in Elderly Patients With Trauma of the Hip","status":"TERMINATED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2016-05","conditions":"Hip Fractures, Anesthesia","enrollment":239},{"nctId":"NCT03529097","phase":"PHASE4","title":"Evaluation of the Roll of IV Fluids in the Treatment of Renal Colic","status":"WITHDRAWN","sponsor":"Sheba Medical Center","startDate":"2018-06-01","conditions":"Renal Colic","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Optalgin, Voltaren, Morphine","genericName":"Optalgin, Voltaren, Morphine","companyName":"Sheba Medical Center","companyId":"sheba-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination of three distinct analgesic and anti-inflammatory agents: Optalgin (metamizole) inhibits prostaglandin synthesis, Voltaren (diclofenac) is an NSAID that blocks COX enzymes, and Morphine is an opioid agonist at mu receptors. Used for Moderate to severe acute pain, Postoperative pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}